Order Article Reprints

Huerta-Yepez S, Gonzalez JD, Sheik N, Beraki S, Kathirvel E, Rodriguez-Frandsen A, Chen P-C, Sargsyan T, Mahammad S, Dybul MR, et al. Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer. Vaccines. 2025; 13(7):749. https://doi.org/10.3390/vaccines13070749

Huerta-Yepez, Sara, Jose D. Gonzalez, Neha Sheik, Senay Beraki, Elango Kathirvel, Ariel Rodriguez-Frandsen, Po-Chun Chen, Tiran Sargsyan, Saleemulla Mahammad, Mark R. Dybul, and et al. 2025. "Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer" Vaccines 13, no. 7: 749. https://doi.org/10.3390/vaccines13070749

Huerta-Yepez, S., Gonzalez, J. D., Sheik, N., Beraki, S., Kathirvel, E., Rodriguez-Frandsen, A., Chen, P.-C., Sargsyan, T., Mahammad, S., Dybul, M. R., Chen, L., Binette, F., & Jewett, A. (2025). Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer. Vaccines, 13(7), 749. https://doi.org/10.3390/vaccines13070749